Market Overview

MannKind Plunges on Securities Offering

Shares of biotech name MannKind (NASDAQ: MNKD) had lost nearly 9 percent on Tuesday after the company filed to sell up to $500 million in mixed securities. Year-to-date, the stock has lost less than 1 percent and over the last 52-weeks, MNKD is down almost 16 percent.

MannKind Corporation is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Posted-In: News Offerings Intraday Update Movers

 

Related Articles (MNKD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters